Zai Lab (ZLAB) Non-Current Assets (2016 - 2026)
Zai Lab (ZLAB) posted Non-Current Assets of $151.0 million for Q1 2026, down 1.37% sequentially from $153.1 million in Q4 2025, and up 14.87% YoY from $131.5 million in Q1 2025.
Zai Lab (ZLAB) Non-Current Assets (2016 - 2026) Analysis & Trends
Zai Lab has reported Non-Current Assets for 11 years, with the latest figure at $151.0 million in Q1 2026.
- Quarterly Non-Current Assets rose 14.87% year-over-year to $151.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $560.1 million (up 10.05% YoY) and the FY2025 annual result came in at $153.1 million, up 13.18% from the prior year.
- Non-Current Assets slipped to $151.0 million in Q1 2026 per ZLAB's latest filing, from $153.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $153.1 million in Q4 2025 and troughed at $83.1 million in Q2 2022.
- A 5-year average of $112.4 million and a median of $107.7 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets decreased 18.63% in 2022, then jumped 48.63% in 2024.
- Over 5 years, Non-Current Assets stood at $95.8 million in 2022, then gained by 0.92% to $96.7 million in 2023, then surged by 39.91% to $135.3 million in 2024, then increased by 13.18% to $153.1 million in 2025, then dropped by 1.37% to $151.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $151.0 million, $153.1 million, and $126.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Zai Lab | 2.91 Bn | 2.20 Bn | 58.15 Mn | 160.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.76 Mn |
| Mar 31, 2026 | 151.01 Mn |
| Dec 31, 2025 | 153.10 Mn |
| Sep 30, 2025 | 125.99 Mn |
| Jun 30, 2025 | 130.04 Mn |
| Mar 31, 2025 | 131.46 Mn |
| Dec 31, 2024 | 135.27 Mn |
| Sep 30, 2024 | 124.80 Mn |
| Jun 30, 2024 | 117.45 Mn |
| Mar 31, 2024 | 99.80 Mn |
| Dec 31, 2023 | 96.69 Mn |
| Sep 30, 2023 | 83.96 Mn |
| Jun 30, 2023 | 88.87 Mn |
| Mar 31, 2023 | 97.78 Mn |
| Dec 31, 2022 | 95.80 Mn |
| Sep 30, 2022 | 88.68 Mn |
| Jun 30, 2022 | 83.13 Mn |
| Mar 31, 2022 | 107.66 Mn |
| Dec 31, 2021 | 109.08 Mn |
| Sep 30, 2021 | 108.99 Mn |